TFG Asset Management GP Ltd Boosts Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

TFG Asset Management GP Ltd lifted its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 3.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,250,000 shares of the company's stock after buying an additional 250,000 shares during the quarter. Autolus Therapeutics comprises about 4.8% of TFG Asset Management GP Ltd's holdings, making the stock its 4th largest position. TFG Asset Management GP Ltd owned 3.10% of Autolus Therapeutics worth $19,388,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Candriam S.C.A. acquired a new stake in Autolus Therapeutics in the fourth quarter worth $7,500,000. AXA S.A. bought a new position in shares of Autolus Therapeutics during the 4th quarter worth about $4,288,000. Wellington Management Group LLP grew its stake in shares of Autolus Therapeutics by 4.6% in the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock valued at $59,562,000 after buying an additional 1,125,454 shares during the period. Millennium Management LLC increased its position in Autolus Therapeutics by 91.6% in the 4th quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock valued at $3,885,000 after buying an additional 790,437 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Autolus Therapeutics by 145.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company's stock valued at $4,663,000 after buying an additional 761,008 shares in the last quarter. Institutional investors own 72.83% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on AUTL. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Truist Financial decreased their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Wells Fargo & Company cut their price target on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research note on Friday, March 21st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $9.32.

Autolus Therapeutics Trading Up 4.1%

Shares of AUTL traded up $0.06 during trading hours on Thursday, reaching $1.53. 968,765 shares of the stock traded hands, compared to its average volume of 1,484,210. Autolus Therapeutics plc has a 52 week low of $1.11 and a 52 week high of $5.00. The company has a market cap of $407.20 million, a price-to-earnings ratio of -1.26 and a beta of 1.77. The stock has a fifty day simple moving average of $1.43 and a 200 day simple moving average of $2.11.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The business had revenue of $8.98 million for the quarter, compared to analysts' expectations of $1.59 million. Analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.